Jul 7, 2020
Both cabotegravir and oral tenofovir/emtricitabine (TDF/FTC) shown to have high efficacy for pre-exposure prophylaxis (PrEP)
Researchers from the HIV Prevention Trials Network (HPTN) announced today that the HPTN 083 clinical trial showed that a pre-exposure prophylaxis (PrEP) regimen containing long-acting cabotegravir (CAB LA) injected once every 8 weeks was superior to daily oral tenofovir/emtricitabine (TDF/FTC) for HIV prevention among cisgender men and transgender women who have sex with men. The results were reported at the 23rd International AIDS Conference (AIDS 2020: Virtual). HPTN 083 is a randomized, controlled, double-blind study comparing the safety and efficacy of a regimen including CAB LA to daily TDF/FTC at 43 sites around the world.
Press Release HPTN 083 FAQ Press Coverage
AIDS 2020 Presentation July 16 Public Webinar